反応式
C(O[C:4](=[O:13])[CH2:5][C:6]([C:8]1[O:12][N:11]=[CH:10][CH:9]=1)=O)C.[NH:14]([C:16]1[CH:35]=[CH:34][C:19]([C:20]([NH:22][CH:23]2[CH2:28][C:27]([CH3:30])([CH3:29])[N:26]([CH3:31])[C:25]([CH3:33])([CH3:32])[CH2:24]2)=[O:21])=[CH:18][CH:17]=1)[NH2:15].C(O)C>C(O)(=O)C>[O:12]1[C:8]([C:6]2[NH:15][N:14]([C:16]3[CH:35]=[CH:34][C:19]([C:20]([NH:22][CH:23]4[CH2:24][C:25]([CH3:32])([CH3:33])[N:26]([CH3:31])[C:27]([CH3:30])([CH3:29])[CH2:28]4)=[O:21])=[CH:18][CH:17]=3)[C:4](=[O:13])[CH:5]=2)=[CH:9][CH:10]=[N:11]1参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
反応条件
- 温度
- 65 °C
実験手順
3-Isoxazol-5-yl-3-oxo-propionic acid ethyl ester (49 mg) and 4-Hydrazino-N-(1,2,2,6,6-pentamethyl-piperidin-4-yl)-benzamide (93 mg) were dissolved into ethanol (2.5 ml) and acetic acid (0.3 ml) and the solution stirred at 65° C. for 2 h. Concentration in vacuo and purification by HPLC gave the expected product. LC/MS: main peak is product (m/z: 424.3)
後処理
- concentrationConcentration
- customin vacuo and purification by HPLC
出典と根拠
- ORDレコード
- ord-b749f24f24fe4fcba056b5e8b41063bc
- 出典データセット
- uspto-grants-2012_04
- 特許番号
- US08163757B2
関連ノート
読み込み中…